Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.73
AMRS's Cash to Debt is ranked higher than
59% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. AMRS: 0.73 )
AMRS' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.73

Equity to Asset -0.49
AMRS's Equity to Asset is ranked lower than
52% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. AMRS: -0.49 )
AMRS' s 10-Year Equity to Asset Range
Min: -0.93   Max: 0.87
Current: -0.49

-0.93
0.87
F-Score: 2
Z-Score: -5.16
M-Score: -1.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -275.23
AMRS's Operating margin (%) is ranked higher than
62% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. AMRS: -275.23 )
AMRS' s 10-Year Operating margin (%) Range
Min: -312.41   Max: -98.14
Current: -275.23

-312.41
-98.14
Net-margin (%) -484.03
AMRS's Net-margin (%) is ranked higher than
59% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. AMRS: -484.03 )
AMRS' s 10-Year Net-margin (%) Range
Min: -571.78   Max: -99.77
Current: -484.03

-571.78
-99.77
ROA (%) -81.68
AMRS's ROA (%) is ranked higher than
56% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. AMRS: -81.68 )
AMRS' s 10-Year ROA (%) Range
Min: -106.46   Max: -34.14
Current: -81.68

-106.46
-34.14
ROC (Joel Greenblatt) (%) -73.45
AMRS's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. AMRS: -73.45 )
AMRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.97   Max: -78.77
Current: -73.45

-297.97
-78.77
Revenue Growth (%) -53.60
AMRS's Revenue Growth (%) is ranked higher than
58% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. AMRS: -53.60 )
AMRS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -53.6
Current: -53.6

EBITDA Growth (%) -17.70
AMRS's EBITDA Growth (%) is ranked higher than
68% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. AMRS: -17.70 )
AMRS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -17.7
Current: -17.7

EPS Growth (%) -28.00
AMRS's EPS Growth (%) is ranked higher than
64% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. AMRS: -28.00 )
AMRS' s 10-Year EPS Growth (%) Range
Min: 0   Max: -28
Current: -28

» AMRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

AMRS Guru Trades in Q4 2012

Paul Tudor Jones 20,600 sh (New)
» More
Q1 2013

AMRS Guru Trades in Q1 2013

Paul Tudor Jones 11,600 sh (-43.69%)
» More
Q2 2013

AMRS Guru Trades in Q2 2013

Paul Tudor Jones 11,600 sh (unchged)
» More
Q3 2013

AMRS Guru Trades in Q3 2013

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Amyris Inc

Billionaires Hold Waning Biotechs 42% Off
Year 2013 has been called the year of the biotech return. According to BioTechNow, the sector is doing better than it has since 2007. One of the highlighted companies today, StemCells Inc. (STEM) just completed its successful IPO last week. Read more...

Ratios

vs
industry
vs
history
P/S 8.78
AMRS's P/S is ranked higher than
81% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 20.06 vs. AMRS: 8.78 )
AMRS' s 10-Year P/S Range
Min: 0.52   Max: 9.69
Current: 8.78

0.52
9.69
EV-to-EBIT -3.47
AMRS's EV-to-EBIT is ranked higher than
74% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMRS: -3.47 )
AMRS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.47

Current Ratio 2.75
AMRS's Current Ratio is ranked higher than
67% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. AMRS: 2.75 )
AMRS' s 10-Year Current Ratio Range
Min: 0.54   Max: 11.36
Current: 2.75

0.54
11.36
Quick Ratio 2.41
AMRS's Quick Ratio is ranked higher than
67% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. AMRS: 2.41 )
AMRS' s 10-Year Quick Ratio Range
Min: 0.37   Max: 11.22
Current: 2.41

0.37
11.22

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.57
AMRS's Price/Median PS Value is ranked higher than
70% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. AMRS: 2.57 )
AMRS' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 2.86
Current: 2.57

0.37
2.86
Forward Rate of Return (Yacktman) -128.14
AMRS's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. AMRS: -128.14 )
AMRS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.8   Max: -13.7
Current: -128.14

-15.8
-13.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3A0.Germany
Amyris, Inc., was formed as a California corporation in 2003 under the name Amyris Biotechnologies, Inc. The Company is a renewable products company. It provides alternatives to petroleum-sourced products used in transportation fuel markets and specialty chemical. The Company uses its proprietary synthetic biology platform to design microbes, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons. The Company develops and commercializes products from these hydrocarbons in markets, including cosmetics, lubricants, flavors and fragrances, polymers and plastic additives, home and personal care products and transportation fuels. The Company develops technology capable of creating microbial strains to produce artemisinic acid - a precursor of artemisinin, an effective anti-malarial drug. It granted a royalty-free license to this technology to Sanofi-Aventis, which currently expects to begin distributing artemisinin-based anti-malarial drugs made through its technology in 2013. Its production operations involve two steps. First, the company produces the target molecule by means of an industrial fermentation process. In certain cases this target molecule is itself the desired end product. In other cases, target molecule must be converted into the desired end product by means of chemical finishing steps where the company uses chemical synthesis of the initial target molecule to produce a final target molecule. It has two operating subsidiaries, Amyris Brasil Ltda., and Amyris Fuels, LLC,. Amyris Brasil oversees the establishment and expansion of Amyris's production in Brazil, and Amyris Fuels was established to help the Company develop fuel distribution capabilities in the United States. The Company competes with both the traditional, largely petroleum-based specialty chemical and fuels products that are used in markets. The Company is subject to a variety of federal, state, local and international laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the U.S., Brazil and other countries.
» More Articles for AMRS

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Netlist Inc, LifePoint Hospitals Inc, Amyris Inc, and Sapient Corp. May 25 2014 
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
Weekly CFO Sells Highlight: SCHW, TIBX, IL, AMRS, BCR, CCOI, CBST Apr 24 2011 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 

More From Other Websites
Braskem Joins Amyris and Michelin to Accelerate the Industrialization and Commercialization of... Sep 09 2014
Using Mean Reversion and Momentum for Possible Advantage Aug 30 2014
Can Amyris (AMRS) Run Higher on Strong Earnings Estimate Revisions? Aug 26 2014
Amyris (AMRS) Shares March Higher, Can It Continue? Aug 22 2014
AMYRIS, INC. Financials Aug 15 2014
Total-Backed Amyris Gets $11 Million for Research on Farnesene Aug 14 2014
AMYRIS, INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
AMYRIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014
Amyris Reports Second Quarter 2014 Financial Results Aug 07 2014
Q2 2014 Amyris Inc Earnings Release - After Market Close Aug 07 2014
AMYRIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Aug 04 2014
First International Commercial Flight Completed With Newly Approved Amyris-Total Aviation Biofuel Jul 31 2014
Zacks Investment Ideas feature highlights: Amyris and Navistar International Jul 28 2014
Amyris: Progressing Nicely Despite Some Large Risks Jul 21 2014
Amyris to Announce Second Quarter Financial Results on Thursday, August 7, 2014 Jul 17 2014
Brazilian Airline GOL to Make First International Commercial Flights With Newly Approved... Jul 09 2014
AMYRIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 30 2014
AMYRIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 18 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK